Cargando…
Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
BACKGROUND: Teicoplanin is a glycopeptide antibiotic that has been used to treat serious, invasive infections caused by Gram-positive bacteria. The area under the drug concentration–time curve (AUC)/minimum inhibitory concentration (MIC) was identified as a pharmacokinetic–pharmacodynamic (PK–PD) pa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822798/ https://www.ncbi.nlm.nih.gov/pubmed/27099534 http://dx.doi.org/10.2147/CPAA.S96143 |
_version_ | 1782425809828446208 |
---|---|
author | Matsumoto, Kazuaki Watanabe, Erika Kanazawa, Naoko Fukamizu, Tomohide Shigemi, Akari Yokoyama, Yuta Ikawa, Kazuro Morikawa, Norifumi Takeda, Yasuo |
author_facet | Matsumoto, Kazuaki Watanabe, Erika Kanazawa, Naoko Fukamizu, Tomohide Shigemi, Akari Yokoyama, Yuta Ikawa, Kazuro Morikawa, Norifumi Takeda, Yasuo |
author_sort | Matsumoto, Kazuaki |
collection | PubMed |
description | BACKGROUND: Teicoplanin is a glycopeptide antibiotic that has been used to treat serious, invasive infections caused by Gram-positive bacteria. The area under the drug concentration–time curve (AUC)/minimum inhibitory concentration (MIC) was identified as a pharmacokinetic–pharmacodynamic (PK–PD) parameter of glycopeptide antibiotics that correlated with bacteriological responses and clinical outcomes. Although optimized dosing regimens based on PK–PD are needed, a PK–PD analysis of teicoplanin against methicillin-resistant Staphylococcus aureus (MRSA) infections has not yet been performed. Thus, this study examined patients with MRSA infections, who were administered with teicoplanin in order to determine the target AUC/MIC ratio. METHODS: This study retrospectively assessed data obtained as part of our routine therapeutic drug monitoring (TDM) of teicoplanin therapy in 46 patients with MRSA infections at Kagoshima University Hospital. Serum concentrations of teicoplanin were determined using a fluorescence polarization immunoassay system and used for a Bayesian PK estimation to estimate AUC for 24 hours (AUC(24)). The MIC value for teicoplanin was determined using a standardized agar dilution method. The effects of teicoplanin were evaluated in terms of bacteriological responses by a quantitative assessment. RESULTS: The estimated AUC(24)/MIC ratios with and without bacteriological responses were 926.6±425.2 µg·h/mL (n=34) and 642.2±193.9 µg·h/mL, respectively (n=12; P<0.05). On the basis of a logistic regression analysis, AUC(24)/MIC ratios of 500 µg·h/mL, 700 µg·h/mL, and 900 µg·h/mL gave probabilities of treatment success of 0.50, 0.72, and 0.87, respectively. Furthermore, using the Kaplan–Meier curve analysis, an AUC(24)/MIC ratio of ≥900 led to a significantly stronger bacteriological response than an AUC(24)/MIC ratio of <900. CONCLUSION: These results suggest that an AUC(24)/MIC ratio of ≥900 µg·h/mL is required to ensure a sufficient bacteriological response. |
format | Online Article Text |
id | pubmed-4822798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48227982016-04-20 Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections Matsumoto, Kazuaki Watanabe, Erika Kanazawa, Naoko Fukamizu, Tomohide Shigemi, Akari Yokoyama, Yuta Ikawa, Kazuro Morikawa, Norifumi Takeda, Yasuo Clin Pharmacol Original Research BACKGROUND: Teicoplanin is a glycopeptide antibiotic that has been used to treat serious, invasive infections caused by Gram-positive bacteria. The area under the drug concentration–time curve (AUC)/minimum inhibitory concentration (MIC) was identified as a pharmacokinetic–pharmacodynamic (PK–PD) parameter of glycopeptide antibiotics that correlated with bacteriological responses and clinical outcomes. Although optimized dosing regimens based on PK–PD are needed, a PK–PD analysis of teicoplanin against methicillin-resistant Staphylococcus aureus (MRSA) infections has not yet been performed. Thus, this study examined patients with MRSA infections, who were administered with teicoplanin in order to determine the target AUC/MIC ratio. METHODS: This study retrospectively assessed data obtained as part of our routine therapeutic drug monitoring (TDM) of teicoplanin therapy in 46 patients with MRSA infections at Kagoshima University Hospital. Serum concentrations of teicoplanin were determined using a fluorescence polarization immunoassay system and used for a Bayesian PK estimation to estimate AUC for 24 hours (AUC(24)). The MIC value for teicoplanin was determined using a standardized agar dilution method. The effects of teicoplanin were evaluated in terms of bacteriological responses by a quantitative assessment. RESULTS: The estimated AUC(24)/MIC ratios with and without bacteriological responses were 926.6±425.2 µg·h/mL (n=34) and 642.2±193.9 µg·h/mL, respectively (n=12; P<0.05). On the basis of a logistic regression analysis, AUC(24)/MIC ratios of 500 µg·h/mL, 700 µg·h/mL, and 900 µg·h/mL gave probabilities of treatment success of 0.50, 0.72, and 0.87, respectively. Furthermore, using the Kaplan–Meier curve analysis, an AUC(24)/MIC ratio of ≥900 led to a significantly stronger bacteriological response than an AUC(24)/MIC ratio of <900. CONCLUSION: These results suggest that an AUC(24)/MIC ratio of ≥900 µg·h/mL is required to ensure a sufficient bacteriological response. Dove Medical Press 2016-03-30 /pmc/articles/PMC4822798/ /pubmed/27099534 http://dx.doi.org/10.2147/CPAA.S96143 Text en © 2016 Matsumoto et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Matsumoto, Kazuaki Watanabe, Erika Kanazawa, Naoko Fukamizu, Tomohide Shigemi, Akari Yokoyama, Yuta Ikawa, Kazuro Morikawa, Norifumi Takeda, Yasuo Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections |
title | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections |
title_full | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections |
title_fullStr | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections |
title_full_unstemmed | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections |
title_short | Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections |
title_sort | pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with mrsa infections |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822798/ https://www.ncbi.nlm.nih.gov/pubmed/27099534 http://dx.doi.org/10.2147/CPAA.S96143 |
work_keys_str_mv | AT matsumotokazuaki pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT watanabeerika pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT kanazawanaoko pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT fukamizutomohide pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT shigemiakari pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT yokoyamayuta pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT ikawakazuro pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT morikawanorifumi pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections AT takedayasuo pharmacokineticpharmacodynamicanalysisofteicoplanininpatientswithmrsainfections |